Application of NKG2A in detecting human NK cells in mouse humanized tumor models
By using NKG2A as a detection target in mouse human tumor models, the problem of detecting human NK cells and human tumor cells is solved, providing a high-sensitivity method, realizing the non-clinical pharmacokinetics of cell therapy drugs Research has improved the accuracy of efficacy and safety assessment.
Patent Information
- Application Number
- CN202111558993.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-20
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-12-20
AI Technical Summary
There is a lack of effective methods in the prior art to detect the retention time and tissue distribution of human NK cells in mouse human tumor models, resulting in insufficient non-clinical pharmacokinetic research on cell therapy drugs, affecting efficacy and safety assessment.
Using NKG2A as the detection target, the expression of NKG2A gene and protein through qPCR technology and immunoblotting is used to distinguish human NK cells from human tumor cells in mouse tissues, providing a high-sensitivity and accurate method for non-clinical drugs. Study on generational dynamics.
Accurate detection in a short time (5-6 hours), improve detection efficiency and sensitivity, reduce uncertainty in cell therapy, enhance the reliability of efficacy and safety assessment, and has important clinical guidance significance.
Smart Images

Figure CN114214430B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and particularly relates to application of NKG2A in detecting human NK cells in a mouse human tumor model. Background Art
[0002] NK cells generally refer to natural killer cells (NK), which are important immune cells in the body. They have rich cytoplasm and contain large azure granules. The content of granules is positively correlated with the killing activity of NK cells, which can secrete perforin and tumor necrosis factor to destroy target cells. NK cells are not only related to anti-tumor, anti-viral infection and immune regulation, but also participate in the occurrence of hypersensitivity reactions and autoimmune diseases in some cases, and can recognize target cells and kill mediators. Common NK cells include peripheral blood-derived NK cells, cord blood-derived NK cells, and NK cells differentiated from hPSCs.
[0003] NK cells do not express genetically rearranged antigen-specific receptors, but rely on a series of receptors encoded by germline genes. NK cell surface activating receptors (NKp46, NKp44, NKp30, NKG2D, etc.) or inhibitory receptors (NKG2A, TIGIT, human inhibitory KIR, mouse Ly49 receptor, etc.). NKG2 family proteins are a class of receptors in a complex receptor-ligand signaling network that have both inhibitory and activating properties and are very attractive targets for the development of immune checkpoint inhibitors. NKG2 protein is a C-type lectin that can dimerize with CD94 on the cell surface. NKG2A is an "inhibitory" member of the NKG2 family, expressed in a subset of CD56hi NK cells, NKT cells, and CD8+αβT cells.
[0004] With the continuous deepening of NK cell research, NK cells have been gradually widely used in clinical practice in recent years. However, in the current existing technology research field, many studies are mainly focused on how to obtain active NK cells, NK function research, NK cell expansion, etc., while there are few reports on methods for detecting NK cells in biological tissues after the obtained NK cells are infused into the therapeutic body. Therefore, there are few research contents on drug metabolism such as the retention time of therapeutic NK cells in the body and the tissue distribution in the body.
[0005] For cell therapy drugs, studying their in vivo pharmacokinetics is an essential step in determining their efficacy and toxic side effects. Unlike traditional drugs, there is currently no clear in vivo pharmacokinetics research method established internationally for the dynamic changes of cell therapy drugs after they enter the body, including the processes and characteristics of absorption, distribution, metabolism and excretion.
[0006] Non-clinical pharmacokinetic studies, especially animal experiments, are very helpful in reducing the uncertainty of cell therapy, increasing efficacy and reducing toxic side effects by studying its dynamics in the body and predicting treatment plans during the evaluation process of new drug development. NK cells are a therapeutic cell drug, so in drug development, it is necessary to clarify relevant research data such as drug metabolism and kinetics, so it is necessary to study the distribution of drugs after entering the organism. NK cells are one of the immune cells in lymphocytes and are cells with strong cell killing ability. Usually NK cells patrol the human body and attack when they find cancer cells or abnormal cells infected by viruses, buying time for other cells such as T cells to attack cancer cells. However, NK cells only account for 10%, so the growth of cancer cells can be controlled by increasing the number of NK cells. At present, NK cell therapy is the most promising seed player, and scientists are constantly studying and expanding NK cell therapy. As an important component of the body's innate immune system, NK cells play an important role in tumor immunity. In the current research field, there are ready-to-use NK cell drugs, but more research needs to be carried out. The current research is not thorough and some are in the clinical stage.
[0007] Exploring the tissue distribution and dynamic changes of NK cells infused into organisms is of great significance for subsequent scientific research and clinical practice. Therefore, establishing a method for detecting allogeneic NK cells in organism tissues is of great significance for NK cell and clinical research.
[0008] At present, the main methods for studying non-clinical pharmacokinetics of cells in experimental animals include animal in vivo imaging (such as fluorescent protein labeling, fluorescent, Fe ion labeling cells), immunohistochemistry, qPCR, etc. Among them, fluorescent protein labeled cells are widely used in animal in vivo imaging, but in non-clinical evaluation, cells with the same production process as clinical use must be used, and fluorescent protein labeled cells cannot be used; after NK cells enter the mouse body, they will continue to proliferate for a relatively long time. After the cells are labeled with fluorescent, Fe ions, etc., they will gradually dilute as the cells proliferate, and the residual fluorescent and Fe ions after cell death will remain in the body for a relatively long time, so it is impossible to truly reflect the survival of cells in the body. Compared with immunohistochemistry, the qPCR method achieves a more sensitive limited analysis of human cells in animals by detecting DNA or RNA expression in the blood or tissues of the subjects in the experiment. The operation is relatively simple and time-saving. Although some DNA sequences that distinguish humans from different animals have been reported in the prior art, they cannot be applied to the study of tissue distribution of non-gene-edited human cells in animals with human tumors, because these human-specific DNA sequences cannot distinguish between therapeutic human cells and human tumor cells. Therefore, it is necessary to establish a method with higher sensitivity, higher accuracy, and more extensive applicability to non-clinical pharmacokinetic studies in NK cell therapy. Summary of the invention
[0009] In view of this, the purpose of the present invention is to provide an application of NKG2A in detecting human NK cells in a mouse human tumor model. NKG2A can distinguish between human cells (NK cells) and human tumor cells in a mouse tumor-bearing tumor model, which is more conducive to non-clinical pharmacokinetics research, and the detection method is more accurate, highly sensitive and short in detection time.
[0010] The present invention provides a method suitable for non-clinical pharmacokinetic studies in NK cell therapy, comprising the following steps:
[0011] In a mouse tumor-bearing model, the NKG2A fragment is used as a detection target to detect the expression level of the sample to be tested, so as to distinguish human NK cells and human tumor cells expressing NKG2A in mouse tissues. The NKG2A fragment is any one of the NKG2A protein, NKG2A gene and NKG2A coding sequence.
[0012] Preferably, the nucleotide sequence of the coding sequence of NKG2A comprises the following DNA fragments;
[0013] 1) A DNA fragment having a nucleotide sequence as shown in SEQ ID NO: 1;
[0014] 2) Based on SEQ ID NO: 1, a DNA fragment with a length of more than 15% is cut.
[0015] Preferably, the nucleotide sequence of the coding sequence of NKG2A is shown in SEQ ID NO:2.
[0016] Preferably, the detection includes detecting the NKG2A gene expression level using qPCR technology and detecting the NKG2A protein expression level using immunoblotting.
[0017] Preferably, the reagent for detecting the expression level of the NKG2A gene using qPCR technology includes a primer pair NKG2A-F1 / NKG2A-R1 for specific amplification of the NKG2A gene;
[0018] The nucleotide sequence of NKG2A-F1 is shown in SEQ ID NO: 3;
[0019] The nucleotide sequence of NKG2A-R1 is shown in SEQ ID NO:4.
[0020] The present invention provides the use of a reagent for detecting the expression amount of NKG2A in preparing a kit for distinguishing human NK cells expressing NKG2A from human tumor cells in a mouse human tumor model.
[0021] The present invention provides a kit for distinguishing human NK cells expressing NKG2A from human tumor cells in a mouse tumor-bearing tumor model, comprising a primer pair NKG2A-F1 / NKG2A-R1 for specifically amplifying the NKG2A gene or an antibody or aptamer that can specifically bind to the NKG2A protein.
[0022] The present invention provides a method suitable for non-clinical pharmacokinetic research in NK cell therapy. The present invention first detects the expression levels of candidate specific genes CD2, NKG2A, and NKp46 in NK cells and MOLM13 cells. The results show that NKG2A and NKp46 are only expressed in human NK cells, but not in MOLM13 cells. Further screening found that NKG2A and NKp46 are not expressed in mouse tissues and MOLM13, NKG2A is only expressed in human NK cells, and NKG2A has a lower detection sensitivity than NKp46. It can be seen that the use of NKG2A fragments as detection targets can distinguish between human cells (NK cells) and human tumor cells in experimental mouse tumor-bearing tumor models, which is conducive to the study of non-clinical pharmacokinetics.
[0023] Further, the application provided by the present invention specifically defines the detection method. The application can be detected in a short time, and the detection time can be shortened to 5-6 hours to complete, which greatly improves the detection efficiency, accuracy and sensitivity (0.01%); the present invention only requires coding sequence extraction, reverse transcription and qPCR reagents during detection, and the cost is low; and because NKG2A is a gene specifically expressed by NK cells, the detection method of the present invention has the characteristics of high accuracy; at the same time, the application provided by the present invention is a non-clinical pharmacokinetic study, especially an animal experiment, which explores the dynamics in the body during the development of cell therapy and predicts the treatment plan, which is of great help in reducing the uncertainty of cell therapy, increasing the efficacy and reducing the toxic side effects, and has important clinical guiding significance. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 It is the structure diagram of the plasmid DNA standard containing NKG2A and NKp46 marker genes;
[0025] Figure 2 This is the linear analysis graph of the average ΔCT value of the plasmid standard;
[0026] Figure 3 This is the linear analysis graph of the average ΔCT value of the cell standard. DETAILED DESCRIPTION
[0027] The present invention provides application of NKG2A in detecting human NK cells in a mouse human tumor model.
[0028] In the present invention, the NKG2A preferably includes any one of NKG2A protein, NKG2A gene and NKG2A coding sequence. The present invention has no special restrictions on the sequence of the NKG2A protein and NKG2A gene, and the sequence of the NKG2A protein and NKG2A gene known in the art can be used. The nucleotide sequence of the NKG2A coding sequence preferably includes the following DNA fragments;
[0029] 1) A DNA fragment having a nucleotide sequence as shown in SEQ ID NO: 1;
[0030] 2) Cutting a DNA fragment with a length of more than 15% based on SEQ ID NO: 1. In the embodiment of the present invention, the expression level of the NKG2A coding sequence shown in SEQ ID NO: 2 (AGCTCCATTTTAGCAACTGAACAGGAAATAACCTATGCGGAATTAAA CCTTCAAAAAGCTTCTCAGGATTTTCAAGGGAATGACAAAACCTATCA CTGCAAAGATTTACCATCAGCTCCAGAGAAGCTCATTGTTGGGATCCTG GGAATTATCTGTCTTATCTTAATGGCCTCTGTGGTAACGATAGTTG) is used to illustrate the high specific expression of NKG2A in human NK cells.
[0031] In the present invention, the detection preferably includes detecting the expression level of NKG2A gene by qPCR technology and detecting the expression level of NKG2A protein by immunoblotting. The reagent for detecting the expression level of NKG2A gene by qPCR technology preferably includes primer pairs NKG2A-F1 and NKG2A-R1 for specific amplification of NKG2A gene. The nucleotide sequence of NKG2A-F1 is shown in SEQ ID NO:3 (AGCTCCATTTTAGCAACTGAACA); the nucleotide sequence of NKG2A-R1 is shown in SEQ ID NO:4 (CAACTATCGTTACCACAGAGGC). The amplified fragment obtained by primer pair NKG2A-F1 / NKG2A-R1 is shown in SEQ ID NO:2. The qPCR technology detection procedure is preferably as follows: 94°C 30s; 94°C 5min, 60°C 15s, 72°C 10s, 40 cycles. The method for detecting protein expression level by immunoblotting is not particularly limited, and the immunoblotting method known in the art can be used. In qPCR detection, the internal reference gene is preferably GAPDH. The amplification primers for GAPDH preferably include GAPDH-F1 and GAPDH-R1. The nucleotide sequence of GAPDH-F1 is shown in SEQ ID NO: 5. The nucleotide sequence of GAPDH-R1 is shown in SEQ ID NO: 6.
[0032] In the embodiment of the present invention, the qPCR technology is used to detect the expression level of the NKG2A gene to prove that the NKG2A gene is only expressed in human NK cells, but not in human tumor cells, and therefore, it can be used as a detection target for distinguishing human NK cells from human tumor cells. Given that the qPCR technology detects that the NKG2A gene is only specifically expressed in human NK cells, it can be reasonably inferred that the product protein of gene expression is only expressed in human NK cells, not in human tumor cells, and therefore, the purpose of distinguishing human NK cells from human tumor cells can also be achieved by detecting the expression amount of the NKG2A protein.
[0033] The present invention provides the use of a reagent for detecting the expression amount of NKG2A in preparing a kit for distinguishing human NK cells from human tumor cells. The reagent includes a primer for specifically amplifying the NKG2A gene or an antibody or aptamer that specifically binds to the NKG2A protein. In the embodiments of the present invention, the primer for specifically amplifying the NKG2A gene is used as an example for illustration, but it should not be understood as a limitation of the present invention.
[0034] The present invention provides a kit for detecting human NK cells in a mouse tumor-bearing tumor model, comprising a primer pair NKG2A-F1 and NKG2A-R1 for specifically amplifying the NKG2A gene or an antibody or aptamer that specifically binds to the NKG2A protein. The primer pair NKG2A-F1 and NKG2A-R1 are the same as those described above and are not described in detail here. The present invention does not impose any special restrictions on the source of the antibody or aptamer that specifically binds to the NKG2A protein, and the antibody or aptamer that can specifically bind to the NKG2A protein known in the art can be used. The kit includes different types of reagents depending on the detection principle. When the kit includes the primer pair NKG2A-F1 and NKG2A-R1, the kit preferably also includes a qPCR amplification reagent and a reverse transcription reagent. When the kit includes an antibody to the NKG2A protein, the kit includes an immunoblotting reagent. The present invention does not impose any special restrictions on the method of using the kit, and the kit can be operated according to the qPCR method known in the art or according to a conventional immunoblotting detection method.
[0035] The present invention provides a method suitable for non-clinical pharmacokinetic studies in NK cell therapy, comprising the following steps:
[0036] Any one of NKG2A protein, NKG2A gene and NKG2A coding sequence is used as a detection target to detect the expression level of the sample to be tested.
[0037] In the present invention, the detection sensitivity of NKG2A gene was detected to be 0.01% (percentage of NK cell number).
[0038] In the present invention, the method for detecting the expression level of the sample to be tested is not particularly limited, and the detection method based on the expression level of protein, gene and coding sequence known in the art can be used, such as RT-qPCR, immunoblotting or enzyme-linked immunosorbent assay, etc. When detecting the expression level of the NKG2A gene, it is preferred to construct a recombinant vector containing the NKG2A gene fragment. The present invention has no particular restrictions on the method for constructing the recombinant vector of the NKG2A gene fragment, and the construction method of the recombinant vector known in the art can be used.
[0039] In the present invention, NKp46 (gene, coding sequence or protein) is expressed only in human NK cells, not in human tumor cells and mice. Therefore, the present invention uses NKG2A in combination with NKp46 to distinguish between human NK cells and human tumor cells for non-clinical pharmacokinetics research. The amplification primer pair for NKp46 gene expression includes NKp46-F1 / NKp46-R1 and NKp46-F2 / NKp46-R2. The nucleotide sequence of the NKp46-F1 is shown in SEQ ID NO:7 (TGGACCCGAAGTGATCTCG). The nucleotide sequence of NKp46-R1 is shown in SEQ ID NO:8 (TCCTTGAGCAGTAAGAACATGC). The nucleotide sequence of the NKp46-F2 is shown in SEQ ID NO:9 (CCACCGAGGGACATACCGAT). The nucleotide sequence of NKp46-R2 is shown in SEQ ID NO:10 (GTGCAAGGCTGGTGTTCTCA). The amplified fragment obtained by amplifying the NKp46 gene by primer pair NKp46-F1 / NKp46-R1 is shown in SEQ ID NO: 11 (TGGACCCGAAGTGATCTCGGGAGAGAAGGTGACCTTCTACTGCCGTCTAGACACTGCAACAAGCATGTTCTTACTGCTCAAGGA). The amplified fragment obtained by amplifying the NKp46 gene by primer pair NKp46-F2 / NKp46-R2 is shown in SEQ ID NO: 12 (CCACCGAGGGACATACCGATGTTTTGGCTCCTATAACAACCATGCCTGGTCTTTCCCCAGTGAGCCAGTGAAGCTCCTGGTCACAGGCGACATTGAGAACACCAGCCTTGCAC). The application of NKG2A combined with NKp46 in distinguishing human NK cells from human tumor cells is conducive to improving the accuracy of the distinction, and at the same time provides important guidance for non-clinical pharmacokinetic studies.
[0040] The application of the NKG2A gene provided by the present invention in detecting human NK cells in a mouse human tumor model is described in detail below in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention.
[0041] The principles and features of the present invention are described below. The examples are only used to explain the present invention and are not used to limit the scope of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art of the present invention. As used herein, the term 'DNA sequence' refers to a DNA sequence encoding a protein, for example, but not limited to, a DNA sequence encoding a protein present in a cell genome.
[0042] In the following examples, the total mRNA extraction method, total mRNA reverse transcription and qPCR detection reagents involved, RNA extraction kits were purchased from Tiangen Biological Company; RNA reverse transcription kits were purchased from Vazyme (Novezan); qPCR kits were purchased from Transgene (Beijing Quanshijin Biotechnology Co., Ltd.). MOLM13 cells were purchased from Nanjing Kebai Biotechnology Co., Ltd. PBNK and iNK came from Anhui Zhongsheng Tracing Source Biotechnology Co., Ltd., where iNK is prepared according to CN202010153358.3, and PBNK is obtained by conventional preparation methods in the art. The method for detecting human NK cells in the mouse tumor-bearing tumor model described in the present invention is not only applicable to PBNK / iNK cells obtained by the above-mentioned preparation method, but also to PBNK / iNK cells obtained by other methods. Mice were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. The primers involved in the embodiments were synthesized at Nanjing KingScript. The plasmid was synthesized by Nanjing KingScript, and its synthesis method is a conventional technology in the art.
[0043] The human embryonic stem cell-derived NK cells described in the present application, such as human embryonic stem cells, are stem cells separated or obtained from human embryos within 14 days of fertilization that have not undergone in vivo development, and are embryonic stem cells or stem cells that have been approved for commercialization.
[0044] Example 1
[0045] Screening of candidate genes
[0046] 1. Screening candidate genes: Through the official website of NCBI, the expression profiles of NK cells and MOLM13 cells were retrieved, and a series of genes were screened that were highly expressed in human NK cells and not expressed or expressed in very few MOLM13 cells (human tumor cells).
[0047] The expression levels of candidate specific genes CD2, NKG2A, and NKp46 in NK cells and MOLM13 cells were detected.
[0048] First, the total mRNA of NK cells and MOLM13 cell samples was extracted using the Tiangen RNA extraction kit (RNAprep Pure Cell / Bacteria Kit, #DP403). According to the amount of 2ug RNA, the mRNA was reverse transcribed into cDNA using the Vazyme RNA reverse transcription kit (HiScript IIQ RT SuperMix for Qprc, #R223-01). Finally, the Transgene qPCR kit ( Top Green qPCR SuperMix, #AQ131), the expression of CD2, NKG2A, and NKp46 genes in NK cells and MOLM13 cells was detected by RT-qPCR detection method, and the reaction system is shown in Table 1. The primer sequences used to amplify the three genes are shown in Table 2.
[0049] Table 1 RT-qPCR reaction system
[0050]
[0051] Table 2 Designed primer sequence list
[0052]
[0053]
[0054] qPCR was performed using a qPCR kit (TransGene, #AQ131), and all operations were performed on ice. The reaction system was 10 μl per well, and the specific reaction system was prepared as shown in Table 1. Three replicate wells were set for each sample, and the qPCR conditions were: 94°C for 30 s; 94°C for 5 s, 60°C for 15 s, and 72°C for 10, 40 cycles, and the CT value was recorded.
[0055] The results of RT-qPCR detection are shown in Table 3. It can be seen that: NKG2A, NKp46-1 and NKp46-2 were not amplified in MOLM13, but were amplified in iNK and PBNK; although the three pairs of primers for CD2 were not amplified in MOLM13, the amplification CT values in PBNK and iNK were too different.
[0056] Table 3 RT-qPCR test results
[0057]
[0058]
[0059] Example 2
[0060] The expression of the screened genes NKG2A and NKp46 in mouse tissues, MOLM13 cells and NK cells was investigated.
[0061] Mouse tissue preparation: prepare a mortar and liquid nitrogen in advance; take out the spleen of the fresh test mouse and place it directly in a mortar filled with liquid nitrogen, add liquid nitrogen while grinding, and keep the liquid nitrogen always present; divide the ground spleen tissue powder into two 1.5ml EB tubes; immediately add 1ml Trizol to one tube and 700μl lysis solution of the DP430 kit to the other tube, vortex thoroughly for lysis for 5min (two RNA extraction methods), and the two extraction methods are shown in Table 4.
[0062] Table 4 Two RNA extraction methods for mouse tissues
[0063]
[0064] Then, RNA extraction, reverse transcription into cDNA and RT-qPCR were performed according to the above method. The primers used were the same as the corresponding primers mentioned above.
[0065] The results of RT-qPCR detection are shown in Table 5. It can be seen from Table 5 that the three pairs of primers are specific primers that can amplify NK cells and are not expressed in mouse tissues and MOLM13.
[0066] Table 5 RT-qPCR test results
[0067]
[0068]
[0069] Note: CT values greater than or equal to 35 were considered as no expression.
[0070] Example 3
[0071] Preparation of plasmid standards and cell standards and determination of detection limits
[0072] 1. Preparation of plasmid standards
[0073] In this embodiment, the vector plasmid is pUC57; pUC57 is a commonly used vector plasmid that does not specifically bind to NKG2A, NKp46 and other gene primers, making the detection more accurate. The vector plasmid is used to prepare plasmid DNA containing NKG2A and NKp46 marker gene structures as a standard product. The structure of the standard product is as follows: Figure 1 The amplification sequences of the three pairs of primers for plasmid synthesis are shown in Table 6.
[0074] Table 6 Plasmid synthesis 3 pairs of primers
[0075]
[0076]
[0077] The three pairs of primers were connected end to end to form a fusion gene (SEQ ID NO: 19, AGCTCCATTTTAGCAACTGAACAGGAAATAACCTATGCGGAATTAAACCTTCAAAAAGCTTCTCAGGATTTTCAAGGGAATGACAAAACCTATCACTGCAAAGATTTACCATCAGCTCCAGAGAAGCTCATTGTTGGGATCCTGGGAATTATCTGTCTTATCTTAATGGCCTCTGTGGTAACGATAGTTGTGGACCCGAAGTGATCTCGGGAGAGAAGGTGACCTTCTACTGCCGTCTAGACACTGCAACAAGCATGTTCTTACTGCTCAAGGACCACCGAGGGACATACCGATGTTTTGGCTCCTATAACAACCATGCCTGGTCTTTCCCCAGTGAGCCAGTGAAGCTCCTGGTCACAGGCGACATTGAGAACACCAGCCTTGCAC) and cloned into the pUC57 vector plasmid (Nanjing GenScript Co., Ltd.):
[0078] Preparation of standard solution: Take out pUC57-NK plasmid (Note: the storage concentration of pUC57-NK is 100ng / μL). Dilute the plasmid to a concentration of 6.79ng / uL. Then dilute the pUC57-NK plasmid with Nuclease-free H2O into a concentration gradient according to Table 7 as plasmid standard samples, and mark them: "Plasmid Standard Solution #1-8". Note: The plasmid copy number is calculated based on the base number of pUC57-NK plasmid (3097bp) according to the following formula I:
[0079] (6.02×10 23 )×(ng×10 -9 ) / (DNA length×660)=copies Formula I
[0080] Table 7 Preparation of plasmid standard samples
[0081]
[0082]
[0083] According to Table 8, the control group mouse tissue cDNA and NK cell cDNA were mixed into corresponding percentages of cell standard samples and marked as: "Cell Standard Solution #1-5".
[0084] Table 8 Preparation of cell standard samples
[0085] Sample No. NK ratio Small cDNA volume in control group NK cell cDNA volume #1 0.001% 90μl 10μl#2 #2 0.01% 90μl 10μl#3 #3 0.1% 90μl 10μl#4 #4 1% 99μl 1 μl#5 #5 100% - 100μl
[0086] Dilute each cDNA sample into the final RT-qPCR template according to Table 9.
[0087] Table 9 Preparation of sample template
[0088]
[0089]
[0090] qPCR was performed on the samples in Table 9 using a qPCR kit (TransGene, #AQ131), and all operations were performed on ice. The reaction system was 10 μl per well, and the specific reaction system was prepared as shown in Table 1. Three replicate wells were set for each sample, and the primer information was shown in Table 10. GADPH is a commonly used internal reference gene in this field.
[0091] Table 10 Primer information
[0092]
[0093] Table 11 qPCR test results of plasmid standards and cell standards
[0094]
[0095]
[0096]
[0097] According to the CT value of the qPCR test results in Table 11, the average ΔCT of the plasmid standard was calculated as shown in Table 12. At the same time, a linear analysis was performed for the corresponding ΔCT at different concentrations. The results are as follows: Figure 2 As shown in the figure, when 6 or more gradient concentrations of plasmid standards are used for linear analysis, the linear R 2 Always less than 0.99 ( Figure 2 ), when 5 or less gradient concentrations of plasmid standards are used for linear analysis, the linear R 2 Can present greater than 0.99 (see Figure 3 ), therefore, the ΔCT of plasmid standard #4 was selected as the standard for judging the minimum detection amount of NKG2A primers, that is, when the ΔCT value was <19.55, it was determined that NK cells existed and could be detected.
[0098] Table 12 Plasmid Standard ΔCT
[0099] name ΔCT Plasmid Standard #1(0) 21.95 Plasmid Standard #2(10) 21.26 Plasmid Standard #3(100) 20.51 <![CDATA[Plasmid Standard #4 (10 3 )]]> 19.55 <![CDATA[Plasmid Standard #5 (10 4 )]]> 17.405 <![CDATA[Plasmid Standard #6 (10 5 )]]> 14.10667 <![CDATA[Plasmid Standard #7 (10 6 )]]> 10.84667 <![CDATA[Plasmid Standard #8 (10 7 )]]> 7.58
[0100] The average ΔCT value of the cell standard was calculated as shown in Table 13. According to the ΔCT value <19.55, the lower limit of NK cell detection was obtained to be cell standard #2 (0.01%).
[0101] Table 13 Cell Standards ΔCT
[0102]
[0103]
[0104] Example 4
[0105] Detection of human NK cells in various tissues of mouse tumor-bearing models
[0106] In the mouse tumor model injected with human NK cells, the expression of NKG2A gene was detected by RT-qPCR to detect human NK cells. A tumor-bearing mouse control group and a tumor-bearing mouse treatment group were set up in the experimental group, and the liver, spleen, and lung of the mice were taken 4h and 2d after the injection of NK cell treatment to detect the distribution of human NK cells in these tissues.
[0107] Plasmid standards and cell standards were prepared according to the method described in Example 2.
[0108] Mouse tissue was prepared (for preparation method, see Example 1), RNA was extracted and reversed into cDNA, and mixed with H2O at a ratio of 1:1, see Table 9 (#10, #11, #12), and the detection method was see Example 2.
[0109] The expression of NKG2A gene in cells was detected by RT-qPCR detection method (method see Example 1), and the reaction system is shown in Table 1. The NKG2A primers used were the same as in Example 2, and each sample was tested 3 times, and the results are shown in Table 14. The experimental data of the standard product refer to the results of Table 11 in Example 2, and the test was carried out at the same time under the same conditions.
[0110] Table 14 RT-qPCR test results of the tested samples
[0111]
[0112]
[0113] Note: When the ΔCT value is <19.55, it is determined that NK cells exist and can be detected. Alternatively, when the CT value is detected and the experimental group is less than the control group, it can also be considered that NK cells are detected and NK cells exist.
[0114] The above experimental results show that: after the injection of human NK cells into tumor-bearing mice, no NK cells were detected in the liver and lungs at 4 hours, but NK cells could be detected in the liver and lungs after 2 days of treatment; while human NK cells could be detected in the spleen of mice at 4 hours, but no human NK cells were detected after 2 days.
[0115] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention. Sequence Listing <110> Anhui Zhongsheng Suyuan Biotechnology Co., Ltd. <120> Application of NKG2A in detecting human NK cells in mouse humanized tumor models <160> 19 <170> SIPOSequenceListing 1.0 <210> 1 <211> 648 <212> DNA <213> Artificial Sequence <400> 1 atggataacc aaggagtaat ctactcagac ctgaatctgc ccccaaaccc aaagaggcag 60 caacgaaaac ctaaaggcaa taaaagctcc attttagcaa ctgaacagga aataacctat 120 gcggaattaa accttcaaaa agcttctcag gattttcaag ggaatgacaa aacctatcac 180 tgcaaagatt taccatcagc tccagagaag ctcattgttg ggatcctggg aattatctgt 240 cttatcttaa tggcctctgt ggtaacgata gttgttatattc cctcacgtca ttgtggccat 300 tgtcctgagg agtggattac atattccaac agttgttat acattggtaa ggaaagaaga 360 acttgggaag agagtttgct ggcctgtact tcgaagaact ccagtctgct ttctatagat 420 aatgaagaag aaatgaaatt tctgtccatc atttcaccat cctcatggat tggtgtgttt 480 cgtaacagca gtcatcatcc atgggtgaca atgaatggtt tggctttcaa acatgagata 540 aaagactcag ataatgctga acttaactgt gcagtgctac aagtaaatcg acttaaatca 600 gcccagtgtg gatcttcaat aatatatcat tgtaagcata agctttag 648 <210> 2 <211> 190 <212> DNA <213> Artificial Sequence <400> 2 agctccattt tagcaactga acaggaaata acctatgcgg aattaaacct tcaaaaagct 60 tctcaggatt ttcaagggaa tgacaaaacc tatcactgca aagatttacc atcagctcca 120 gagaagctca ttgttgggat cctgggaatt atctgtctta tcttaatggc ctctgtggta 180 acgatagttg 190 <210> 3 <211> 23 <212> DNA <213> Artificial Sequence <400> 3 agctccattt tagcaactga aca 23 <210> 4 <211> 22 <212> DNA <213> Artificial Sequence <400> 4 caactatcgt taccacagag gc 22 <210> 5 <211> 20 <212> DNA <213> Artificial Sequence <400> 5 caccatcttc caggagcgag 20 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <400> 6 gactccacga cgtactcagc 20 <210> 7 <211> 19 <212> DNA <213> Artificial Sequence <400> 7 tggacccgaa gtgatctcg 19 <210> 8 <211> twenty two <212> DNA <213> Artificial Sequence <400> 8 tccttgagca gtaagaacat gc 22 <210> 9 <211> 20 <212> DNA <213> Artificial Sequence <400> 9 ccaccgaggg acataccgat 20 <210> 10 <211> 20 <212> DNA <213> Artificial Sequence <400> 10 gtgcaaggct ggtgttctca 20 <210> 11 <211> 84 <212> DNA <213> Artificial Sequence <400> 11 tggacccgaa gtgatctcgg gagagaaggt gaccttctac tgccgtctag acactgcaac 60 aagcatgttc ttactgctca agga 84 <210> 12 <211> 113 <212> DNA <213> Artificial Sequence <400> 12 ccaccgaggg acataccgat gttttggctc ctataacaac catgcctggt ctttccccag 60 tgagccagtg aagctcctgg tcacaggcga cattgagaac accagccttg cac 113 <210> 13 <211> twenty two <212> DNA <213> Artificial Sequence <400> 13 tcaagagagg gtctcaaaac ca 22 <210> 14 <211> twenty three <212> DNA <213> Artificial Sequence <400> 14 ccattcatta cctcacaggt cag 23 <210> 15 <211> twenty three <212> DNA <213> Artificial Sequence <400> 15 acctgtgagg taatgaatgg aac 23 <210> 16 <211> twenty one <212> DNA <213> Artificial Sequence <400> 16 gtggtccact tgtgtgtgat g 21 <210> 17 <211> twenty two <212> DNA <213> Artificial Sequence <400> 17 agcctgagtg caaaattcaa gt 22 <210> 18 <211> twenty one <212> DNA <213> Artificial Sequence <400> 18 aaaacgagca gtgccacaaa g 21 <210> 19 <211> 387 <212> DNA <213> Artificial Sequence <400> 19 agctccattt tagcaactga acaggaaata acctatgcgg aattaaacct tcaaaaagct 60 tctcaggatt ttcaagggaa tgacaaaacc tatcactgca aagatttacc atcagctcca 120 gagaagctca ttgttgggat cctgggaatt atctgtctta tcttaatggc ctctgtggta 180 acgatagttg tggacccgaa gtgatctcgg gagagaaggt gaccttctac tgccgtctag 240 acactgcaac aagcatgttc ttactgctca aggaccaccg agggacatac cgatgttttg 300 gctcctataa caaccatgcc tggtctttcc ccagtgagcc agtgaagctc ctggtcacag 360 gcgacattga gaacaccagc cttgcac 387
Claims
1. A method for detecting human iNK cells in a mouse human tumor model, characterized in that: The following steps are involved: In a mouse tumor-bearing model, the NKG2A fragment is used as a detection target to detect the expression level of the sample to be tested, so as to distinguish the human iNK cells expressing NKG2A in the mouse tissue from the human tumor cells not expressing NKG2A to determine the distribution of the human iNK cells in the mouse tissue, wherein The detection includes detecting the expression level of NKG2A gene using qPCR technology; Reagents for detecting the expression level of the NKG2A gene using qPCR technology include a primer pair NKG2A-F1 / NKG2A-R1 for specifically amplifying the NKG2A gene; The nucleotide sequence of NKG2A-F1 is shown in SEQ ID NO: 3; The nucleotide sequence of NKG2A-R1 is shown in SEQ ID NO:
4.
2. The method according to claim 1, characterized in that: The nucleotide sequence of the coding sequence of the NKG2A fragment is shown in SEQ ID NO:
2.
3. Use of a reagent for detecting the expression of NKG2A in the preparation of a kit for distinguishing human iNK cells expressing NKG2A from human tumor cells not expressing NKG2A in a mouse human tumor model to determine the distribution of the human iNK cells in mouse tissues, wherein the reagent for detecting the expression of NKG2A includes a primer pair NKG2A-F1 / NKG2A-R1 for specifically amplifying the NKG2A gene; The nucleotide sequence of NKG2A-F1 is shown in SEQ ID NO: 3; The nucleotide sequence of NKG2A-R1 is shown in SEQ ID NO:4.
Citation Information
Patent Citations
Method for differentiating human pluripotent stem cells into natural killer cells and application
CN111235105A
Method and kit for discriminating between breast cancer and benign breast disease
CN102918164A
Neutralization of inhibitory pathways in lymphocytes
CN107001466A
NKG2A antibody as well as preparation method and application thereof
CN111153995A
CD94 and NKG2A gene humanized non-human animal as well as preparation method and application thereof
CN113429472A
